Google-backed 23andMe hits major milestone: 100,000 users in DNA database
By Peter Delevett,
Mercury News
| 06. 15. 2011
Mountain View genomics startup 23andMe just hit a milestone: As of Wednesday, 100,000 people have uploaded their genetic code to the 4-year-old company's database.
Co-founder and CEO Anne Wojcicki says her scientists now have one of the world's largest genetic databases, which will enable them to do "a tremendous amount of discovery" into the possible causes of ailments such as Parkinson's disease. The company is also helping customers better understand their own DNA, the genetic blueprint that determines everything from whether someone is prone to breast cancer to whether their urine smells funny after eating asparagus (for 70 percent of us, the answer's yes on the latter).
But critics worry that 23andMe and other such genomics companies are misleading consumers with DNA profiles that don't tell nearly as much about their health -- good or bad -- as many might think. And in 23andMe's case, they've raised questions about the fact that one of the company's chief financial backers is Google (GOOG) -- whose co-founder, Sergey Brin, is Wojcicki's husband.
In a rare interview, Wojcicki spoke frankly about those controversies...
Related Articles
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
By Robert Resta, The DNA Exchange | 07.22.2024
Medical geneticists and genetic counselors have an often complicated and at times tense relationship with people with disabilities, their families, advocates, and scholars. Geneticists are strong advocates and supporters for all of their patients, regardless of their abilities and disabilities...
By Katherine Bourzac, Nature | 07.10.2024
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...